EZH2 and triple-negative breast carcinoma: Moreover, E7 downregulated EZH2-mediated downstream genes, suggesting its ability to eliminate the nonenzymatic oncogenic role of EZH2.465 This superior therapeutic activity of EZH2 degraders, YM181, over inhibitors was validated in a xenograft mouse model using the SU-DHL-6 cell line.466 Moreover, a series of VHL-based EZH2 PROTACs were developed, among which MS8815, featuring a longer linker, almost completely degrades EZH2 in triple-negative breast cancer cells.